Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety

Expert Opinion on Drug Safety
Bruce PrennerBarry Lutsky

Abstract

Antihistamines are widely used to treat allergic rhinitis (AR) and chronic idiopathic urticaria (CIU) in adults and children. Desloratadine is a once-daily oral antihistamine with a favourable sedation profile that is approved for the treatment of AR and CIU. Phenotypic polymorphism in the metabolism of desloratadine has been observed, such that some individuals have a decreased ability to form 3-hydroxydesloratadine, the major metabolite of desloratadine; such individuals are termed 'poor metabolisers of desloratadine'. This review describes the prevalence of poor metabolisers of desloratadine, quantifies the exposure to desloratadine in poor metabolisers and demonstrates that the increased exposure in poor metabolisers is independent of age when administered at age-appropriate doses. Furthermore, this review demonstrates that the increased exposure to desloratadine in poor metabolisers is not associated with any changes in the safety and tolerability profile of desloratadine, including cardiovascular safety.

References

Jan 1, 1996·Annual Review of Pharmacology and Toxicology·R L Woosley
Feb 1, 1997·The British Journal of Dermatology·B F O'DonnellM W Greaves
May 3, 1997·Lancet·M Lindquist, I R Edwards
Apr 21, 1999·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·J RingR Engst
Apr 22, 1999·Clinical Therapeutics·L M DuBuske
Oct 13, 2000·American Journal of Respiratory and Critical Care Medicine·B LeynaertF Neukirch
Nov 23, 2000·Lancet·U A Meyer
Apr 11, 2001·The Journal of Allergy and Clinical Immunology·R S Geha, E O Meltzer
Apr 12, 2001·The British Journal of Dermatology·C GrattanUNKNOWN British Association of Dermatologists
Jun 27, 2001·Expert Opinion on Investigational Drugs·D K Agrawal
Jul 13, 2001·The Journal of Allergy and Clinical Immunology·D P Skoner
Jul 13, 2001·The Journal of Allergy and Clinical Immunology·E O Meltzer
Mar 29, 2002·Current Allergy and Asthma Reports·Julie C QidwaiJohn M Weiler
Jun 8, 2002·Toxicology Letters·Ilari Paakkari
Aug 9, 2002·European Journal of Pharmacology·John C AnthesRobert E Egan
Aug 10, 2002·Clinical Pharmacokinetics·Melton AffrimeAlbert Cohen
Aug 10, 2002·Clinical Pharmacokinetics·Christopher BanfieldMelton Affrime
Aug 10, 2002·Clinical Pharmacokinetics·Christopher BanfieldMelton Affrime
Oct 24, 2002·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Jeffrey A WilkenRobert Kane
Mar 19, 2003·The Journal of Allergy and Clinical Immunology·F Estelle R SimonsUNKNOWN Desloratadine Study Group
Mar 29, 2003·Journal of the American Academy of Dermatology·Eugene MonroeUNKNOWN Desloratadine Uritcaria Study Group
May 14, 2003·The Journal of Allergy and Clinical Immunology·Thomas B CasaleUNKNOWN Antihistamine Impairment Roundtable
May 24, 2003·Drugs of Today·P. Norman, X. Rabasseda
May 28, 2003·Drugs of Today·P. NormanX. Rabasseda
Aug 9, 2003·Expert Opinion on Drug Safety·Garry M Walsh
Sep 23, 2003·Current Opinion in Allergy and Clinical Immunology·Malcolm W Greaves
May 29, 2004·European Journal of Clinical Pharmacology·E F P M VuurmanJ G Ramaekers
Aug 18, 2004·Fundamental & Clinical Pharmacology·M MolimardM Strolin Benedetti
Oct 22, 2004·Journal of Clinical Pharmacology·Samir GuptaJerry Herron
Jan 1, 2005·BMJ : British Medical Journal·Joshua P CohenCatherine P Cairns

❮ Previous
Next ❯

Citations

Apr 12, 2013·Expert Opinion on Drug Safety·Vanesa González-NúñezJoaquim Mullol
Jul 16, 2009·Drug Metabolism Reviews·Margherita Strolin BenedettiJean-Baptiste Watelet
Jul 16, 2009·Drug Metabolism Reviews·Jean-Marie NicolasMathieu Molimard
Jul 11, 2007·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·R RamanathanJ E Patrick
Oct 2, 2007·Journal of Clinical Pharmacology·Samir K GuptaZaiqi Wang
Jan 25, 2012·Biopharmaceutics & Drug Disposition·Nancy Hakooz, Isam I Salem
Jan 16, 2007·Drug Metabolism and Pharmacokinetics·Kotoko NakataToshihisa Ishikawa
Jan 12, 2019·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Matti K ItkonenJanne T Backman
Oct 2, 2007·American Journal of Clinical Dermatology·Lawrence DuBuske

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.